MEDIA RELEASE

Q2 FY27 standalone revenue grew 652% YoY to ₹44.20 crore; net profit rose to ₹16.01 crore

Ahmedabad, 4 November 2026: Shukra Medtech Limited (formerly Shukra Pharmaceuticals Limited) (NSE: SHUKRAPHAR; BSE: 524632), a listed Indian healthcare company with businesses spanning pharmaceutical formulations, medical technology and analytical testing, today announced its unaudited standalone financial results for the quarter and six months ended 30 September 2026.

Q2 FY27 financial highlights

On a standalone basis, revenue from operations stood at ₹44.20 crore, compared with ₹5.88 crore in Q2 FY26. EBITDA was ₹22.01 crore, with a margin of 49.8%, against negative EBITDA of ₹0.42 crore a year earlier. Profit before tax stood at ₹21.13 crore, compared with ₹0.20 crore in Q2 FY26, while net profit rose to ₹16.01 crore from ₹2.38 crore. In the standalone segment disclosure, MedTech reported segment income of ₹12.51 crore, while the pharmaceutical business reported ₹32.27 crore.

Particulars	Q2 FY27	Q2 FY26	YoY change
Revenue from operations	₹44.20 cr	₹5.88 cr	652%
EBITDA	₹22.01 cr	₹(0.42) cr	Turned positive
EBITDA margin	49.8%	(7.1)%	5,695 bps
Profit before tax	₹21.13 cr	₹0.20 cr	10,549%
Net profit / PAT	₹16.01 cr	₹2.38 cr	573%
PAT margin	36.2%	40.5%	(424) bps

H1 FY27 financial highlights

For the first half of FY27, standalone revenue from operations was ₹67.73 crore, compared with ₹11.27 crore in H1 FY26. EBITDA rose to ₹43.22 crore from ₹0.90 crore, with an EBITDA margin of 63.8%. Profit before tax stood at ₹41.37 crore, compared with ₹1.57 crore, and net profit rose to ₹31.04 crore from ₹3.41 crore.

Particulars	H1 FY27	H1 FY26	YoY change
Revenue from operations	₹67.73 cr	₹11.27 cr	501%
EBITDA	₹43.22 cr	₹0.90 cr	4,709%
EBITDA margin	63.8%	8.0%	5,584 bps
Profit before tax	₹41.37 cr	₹1.57 cr	2,532%
Net profit / PAT	₹31.04 cr	₹3.41 cr	811%
PAT margin	45.8%	30.2%	1,559 bps

Management commentary

Mr. Dakshesh Shah, Chairman and Managing Director, Shukra Medtech Limited, said:

"For most of its thirty-three years, Shukra was a domestic formulations company of modest size. The standalone numbers we are reporting today — revenue of ₹44.20 crore for the quarter and ₹67.73 crore for the half year, with net profit of ₹16.01 crore and ₹31.04 crore, respectively — describe a different company.

This quarter sets the foundation for that evolution. In terms of financials - what has changed is exports. This year, overseas customers account for the bulk of our growth, and serving them has meant higher inventory, longer receivable cycles and a sharper discipline on quality than the domestic trade ever demanded of us. We take that trade-off willingly. It is a comparatively new business for us, and our first task is to make it a repeatable one rather than a good half year.

Alongside this, our priority is to grow the MedTech arm. It will take a few quarters to scale, but it matters most for our long-term growth. Our years in pharmaceuticals have shown us where the gaps in healthcare are and the opportunities beyond our traditional business. We will keep strengthening the pharma operations while we build that platform."

About Shukra Medtech Limited

Established in 1993 and headquartered in Ahmedabad, Shukra Medtech Limited (formerly Shukra Pharmaceuticals Limited) operates across pharmaceutical formulations, medical consumables, MedTech and analytical testing. Its manufacturing operations are based in Gujarat, with customers in India and overseas. The Company is listed on NSE (SHUKRAPHAR) and BSE (524632).

Safe harbour

This release may contain forward-looking statements regarding strategy, expansion and future performance. Actual outcomes may differ because of changes in market conditions, regulation, demand, costs or execution. The Company undertakes no obligation to update forward-looking statements except as required by law.

For further information

Shukra Medtech Limited
Shivkant Dhakad
Company Secretary & Compliance Officer
corporate@shukrapharmaceuticals.com

INVESTOR RELATIONS
Tuvis Consultants
Sandhya Dubey | Founding Partner
Email: sandhya@tuvisconsultants.com

तुविस् | tuvis
growth strength and Intelligence